First study on personalised asthma care shows benefit for some
Children homozygous for a particular beta-2 receptor allele had better quality of life on personalised regimen
AusDoc brings you the latest news from the European Respiratory Society Congress 2020.
The first study to target asthma treatment according to beta-2 adrenergic genotype suggests that children homozygous for a particular allele might have a clinically meaningful benefit.
In the study, reported at the European Respiratory Society international virtual congress (ERS 2020), 241 UK children were randomised to standard care or personalised care determined by their genotype.
All participants (age range 12-18 years) had their beta-2 receptor genotype determined from a buccal swab.
